Schott Pharma AG & Co. KGaA (ETR:1SXP) said on Wednesday it has increased its full-year revenue and earnings guidance after resolving a dispute with a key glass syringe customer that had prompted a profit warning in December 2025.
The German pharmaceutical packaging specialist reported preliminary third-quarter figures showing roughly 8% constant-currency revenue growth and an EBITDA margin of about 27%.
Those preliminary results outpaced market expectations from the Vara Consensus as of July 6, which forecast 3.5% revenue growth and a 27.5% EBITDA margin for the period.
For fiscal year 2026, Schott Pharma raised its constant-currency revenue growth guidance to a range of 5% to 6%, up from a previous range of 2% to 5%. The company also adjusted its EBITDA margin target to between 27% and 28%, from an earlier target of approximately 27%.
Both revised targets sit above the prevailing market consensus cited by the company, which projected 3.2% revenue growth and a 27.2% EBITDA margin.
Schott Pharma said the stronger outlook stems from three main elements: robust business performance to date, expectations for the fourth quarter, and the recently concluded settlement with the glass syringe customer. The company noted that the agreement contains "both revenue-related and compensation components, which will have an impact on future periods."
Market reaction included an analyst upgrade. RBC Capital Markets raised its recommendation on Schott Pharma to "outperform" from "sector perform" and increased its price target to 21 from 18. The broker said it had been looking for a resolution to the syringe dispute and evidence of a turning point before upgrading, and described Wednesday's announcement as meeting those conditions.
The settlement with the glass syringe customer and the preliminary Q3 metrics together provided the company with the basis to lift its guidance. The firm emphasized that certain elements of the agreement will affect future reporting periods, indicating that the revised outlook incorporates both near-term performance and terms of the customer settlement.
Investors and market watchers will observe how fourth-quarter outcomes and the accounting of settlement components feed into final results and future guidance updates.